Company profile

Digital Diagnostics

AI screeningStrong positionFounded 2010 (as IDx)

Autonomous AI diagnosis of diabetic retinopathy from fundus images — the first autonomous AI cleared in any field of medicine.

About

Marketed LumineticsCore (formerly IDx-DR), the first FDA De Novo-authorized autonomous AI diagnostic (2018): the system, not a doctor, makes the referral decision at the point of care. Focus today is workflow integration and expanding into primary care.

HQ: Coralville, Iowa, USA

Funding

$75M Series B (Aug 2022, KKR-led); >$130M total stated by company
Tracxn lists ~$194M across 10 rounds. No new round or exit found through Aug 2026.